Recall Announcement
A single lot of a popular thyroid medication is being recalled after testing showed the batch may be superpotent. According to the Food & Drug Administration, the recall applies to Thyroid Tablets, USP 30 mg produced by Alabama-based Vitruvias Therapeutics Inc.
Specifically, the recall applies to lot number 504950, which was distributed nationwide to Vitruvias Therapeutics' direct accounts from Jan. 31, 2025 to Sept. 30, 2025. The pills have an expiration date of 9/30/26 and are marked with a National Drug Code of 69680-166-00. The details can be located on the medication's label.
Scope of the Recall
Approximately 3,655 units of the pills were distributed and 1,955 were sold to consumers. So far, Vitruvias Therapeutics Inc. is unaware of any reports of adverse events related to this recall.
Health Risks and FDA Guidance
The FDA warns that consumption of superpotent thyroid medication can cause hyperthyroidism (overactive thyroid). In turn, patients may experience weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate, or heart rhythm disturbances.
The elderly, pregnant women and infants are at the greatest risk of being impacted by a superpotent thyroid medication. For the elderly, there's risk of cardiac issues. For pregnant women, overtreatment of hypothyroidism in pregnancy is associated with a higher rate of maternal and fetal complications, the FDA warns.
Infants may be impacted by negative effects on growth and development.
For those taking the recalled medication, the FDA says they should not discontinue use without contacting their healthcare provider to find a replacement medication.